✨ Free AI Report
Trevena, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Trevena, Inc.
Company Research

Trevena, Inc.: Business Overview, Financials & Competitive Analysis

Trevena, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Trevena represents a speculative biotech play dependent on OLINVYK market adoption and pipeline advancement, with execution risk outweighing technological advantages. Trevena has achieved FDA approval for OLINVYK and operates with differentiated biased ligand technology, but faces significant headwinds including minimal revenues, extremely low market cap ($1M), and trading on OTC.

What is Trevena, Inc.'s industry? Trevena, Inc. (trevena.com) operates in Biopharmaceuticals - CNS Disorders. AskCyborg classifies Trevena, Inc. under Biopharmaceuticals - CNS Disorders in its company registry.

Trevena is a clinical-stage biopharmaceutical company focused on developing innovative medicines for central nervous system disorders using biased ligand technology. The company's FDA-approved lead product OLINVYK (ol...

4/ 10Mixed

Cyborg Score thesis

Trevena represents a speculative biotech play dependent on OLINVYK market adoption and pipeline advancement, with execution risk...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - CNS Disorders
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Trevena, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Trevena, Inc.

AskCyborg analysts argue the bull and bear cases for Trevena, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Trevena, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Trevena, Inc. Overview

Pro stress-test →

Trevena is a clinical-stage biopharmaceutical company focused on developing innovative medicines for central nervous system disorders using biased ligand technology. The company's FDA-approved lead product OLINVYK (oliceridine) targets acute pain management, with a pipeline addressing conditions including migraine, opioid use disorder, and neuropathic pain.

Strategic Profile

Pro stress-test →

Trevena leverages proprietary G-protein coupled receptor (GPCR) biased ligand technology licensed from Duke University to create drugs with improved efficacy and reduced side effects. The company operates as a virtual organization with approximately 23 employees, focusing on commercial execution of OLINVYK while advancing pipeline candidates through collaboration with academic institutions and the NIH.

Competitive Landscape

Pro stress-test →

Trevena competes in the biopharmaceutical space against NGM Biopharmaceuticals, Array BioPharma, and Threshold Pharmaceuticals, as well as broader pain management competitors including traditional opioid manufacturers. Trevena's competitive advantage lies in its biased ligand approach, which targets reduced side effects compared to conventional therapies, but faces headwinds from opioid stigma and regulatory scrutiny.

Industry Context

Trevena, Inc. operates in Biopharmaceuticals - CNS Disorders.

Key facts

Founded: 2007 · Headquarters: Chesterbrook, Pennsylvania · Employees: 23 · Revenue: $3.1M (2022) · Market cap: $1.03M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Trevena, Inc..

  • FDA-approved OLINVYK provides regulatory validation but sales have not materialized into meaningful revenue ($3.1M in 2022)
  • Company transferred certain assets to Jiangsu Nhwa Pharmaceutical in January 2026, suggesting strategic repositioning
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Assignment and Release Agreement with Jiangsu Nhwa Pharmaceutical for asset transfer
  • April 2025Coverage initiated by analysts at StockNews.com on NASDAQ listing
  • +1 moreTrack every material event for Trevena, Inc. as it happens. Explore monitoring →
Get alerted when Trevena, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

NGM BiopharmaceuticalsDiscovery and development of medicines for various diseases using biologic drug candidates→Array BioPharmaTargeted small molecule oncology and inflammatory disease therapeutics→Traditional Opioid ManufacturersEstablished pain management solutions→

Compare Trevena, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Trevena, Inc. operates in Biopharmaceuticals - CNS Disorders. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - CNS Disorders research →
NEW · MCP server

Ask your AI assistant about Trevena, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Trevena, Inc. and its top competitor on Cyborg Score”
“What did Trevena, Inc. do this quarter?”
“Is Trevena, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Trevena, Inc. do?+
Trevena is a clinical-stage biopharmaceutical company focused on developing innovative medicines for central nervous system disorders using biased ligand technology. The company's FDA-approved lead product OLINVYK (ol...
What is Trevena, Inc.'s Cyborg Score?+
Trevena, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Trevena, Inc.'s main competitors?+
Named competitors include NGM Biopharmaceuticals, Array BioPharma, Traditional Opioid Manufacturers. The full competitive landscape is in the AskCyborg report.
How can I get the full Trevena, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Trevena, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Trevena, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.